Corporate VC fund of Vetter Pharma family office investing in highly differentiated technical solutions that become future standards of care in medicines and health tech.
RV Invest backed 1 Y Combinator company.

Discovering bispecific antibody drug-conjugates (BsADC) against cancer
Auto-detected from RV Invest's website.
PhD in computational chemistry with 10+ years biotech experience and prior VC investing at RBV Capital and SCOR.
CEO of Diagonal Therapeutics, PhD in Biophysics from Harvard, former CDO at Morphic and COO at Dragonfly.
PhD in Neuroscience from EPFL, MBA from St. Gallen, prior VC experience at +ND Capital and Ysios Capital.
MBA from SDA Bocconi, CEO of OncoBeta, board member in healthcare companies, third generation Vetter Pharma owner.
Partner at Petrichor with 15+ years healthcare investing experience, MBA from Wharton, board member at multiple biotech companies.
Former President of Novartis Oncology with 25 years pharma experience, Fortune Top 100 Most Powerful Women.
Focus and check size from the firm's website. Website reachable as of Sept 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.